Literature DB >> 24887261

Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisio's absorption technique.

Fatmanur Tuğcu-Demiröz1, Isabel Gonzalez-Alvarez2, Marta Gonzalez-Alvarez2, Marival Bermejo3.   

Abstract

The aim of the present study was to develop a method for water flux reabsorption measurement in Doluisio's Perfusion Technique based on the use of phenol red as a non-absorbable marker and to validate it by comparison with gravimetric procedure. The compounds selected for the study were metoprolol, atenolol, cimetidine and cefadroxil in order to include low, intermediate and high permeability drugs absorbed by passive diffusion and by carrier mediated mechanism. The intestinal permeabilities (Peff) of the drugs were obtained in male and female Wistar rats and calculated using both methods of water flux correction. The absorption rate coefficients of all the assayed compounds did not show statistically significant differences between male and female rats consequently all the individual values were combined to compare between reabsorption methods. The absorption rate coefficients and permeability values did not show statistically significant differences between the two strategies of concentration correction. The apparent zero order water absorption coefficients were also similar in both correction procedures. In conclusion gravimetric and phenol red method for water reabsorption correction are accurate and interchangeable for permeability estimation in closed loop perfusion method.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atenolol; Cefadroxil; Cimetidine; Doluisio’s Perfusion Technique; Metoprolol; Water-flux correction

Mesh:

Substances:

Year:  2014        PMID: 24887261     DOI: 10.1016/j.ejps.2014.05.016

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat-Biophysical Model and Predictions Based on Caco-2.

Authors:  Isabel Lozoya-Agullo; Isabel Gonzalez-Alvarez; Moran Zur; Noa Fine-Shamir; Yael Cohen; Milica Markovic; Teresa M Garrigues; Arik Dahan; Marta Gonzalez-Alvarez; Matilde Merino-Sanjuán; Marival Bermejo; Alex Avdeef
Journal:  Pharm Res       Date:  2017-12-29       Impact factor: 4.200

2.  Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination.

Authors:  Tamires Guedes Caldeira; Dênia Antunes Saúde-Guimarães; Isabel González-Álvarez; Marival Bermejo; Jacqueline de Souza
Journal:  Daru       Date:  2021-04-22       Impact factor: 3.117

3.  Potentiated serotonin signaling in serotonin re-uptake transporter knockout mice increases enterocyte mass and small intestinal absorptive function.

Authors:  Chasen J Greig; Lucy Zhang; Robert A Cowles
Journal:  Physiol Rep       Date:  2019-11

4.  Cubic Microcontainers Improve In Situ Colonic Mucoadhesion and Absorption of Amoxicillin in Rats.

Authors:  Juliane Fjelrad Christfort; Antonio José Guillot; Ana Melero; Lasse Højlund Eklund Thamdrup; Teresa M Garrigues; Anja Boisen; Kinga Zór; Line Hagner Nielsen
Journal:  Pharmaceutics       Date:  2020-04-14       Impact factor: 6.321

5.  Synthesis and Evaluation of PEG-PR for Water Flux Correction in an In Situ Rat Perfusion Model.

Authors:  Guo Chen; Xingqi Min; Qunqun Zhang; Zhiqiang Zhang; Meiqiang Wen; Jun Yang; Meijuan Zou; Wei Sun; Gang Cheng
Journal:  Molecules       Date:  2020-11-04       Impact factor: 4.411

6.  Integration of In Silico, In Vitro and In Situ Tools for the Preformulation and Characterization of a Novel Cardio-Neuroprotective Compound during the Early Stages of Drug Development.

Authors:  Claudia Miranda; Alejandro Ruiz-Picazo; Paula Pomares; Isabel Gonzalez-Alvarez; Marival Bermejo; Marta Gonzalez-Alvarez; Alex Avdeef; Miguel-Ángel Cabrera-Pérez
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.